Description: Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Home Page: www.sobi.com
TomtebodavAegen 23A
Solna,
112 76
Sweden
Phone:
46 86 97 20 00
Officers
| Name | Title |
|---|---|
| Dr. Guido Oelkers Ph.D. | CEO & President |
| Mr. Henrik Stenqvist | Chief Financial Officer |
| Mr. Torbjörn Hallberg | General Counsel & Head of Legal Affairs |
| Mr. Daniel Rankin | Head of Strategy & Corporate Development |
| Ms. Lena Bjurner | Head of Human Resources |
| Mr. Armin Reininger M.D., Ph.D. | Senior Scientific & Medical Advisor |
| Mr. Norbert Oppitz | Head of International |
| Mr. Sofiane Fahmy | Head of Europe |
| Mr. Duane H. Barnes | Head of North America |
| Mr. Mahmood Ladha | Head of Strategic Transformation Operations |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 20.6612 |
|---|---|
| Trailing PE: | 30.7742 |
| Price-to-Book MRQ: | 2.9069 |
| Price-to-Sales TTM: | 0.3887 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1814 |